Healthcare
Myriad Genetics, Inc.(MYGN)
Live Price
Offline$4.32
-0.23% today
1Y Change
-2.06%
Window
Jun 26, 2025 โ Jun 24, 2026
- Market Cap
- $450.00M
- Revenue Growth
- -1.6%
- EPS Growth
- -180.9%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 26, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Myriad Genetics, Inc. (MYGN) is a Healthcare stock with a market cap of $450.00M and listed on NASDAQ. The stock last traded around $4.32 and down 2.1% across the available one-year price window (Jun 26, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of -1.6%, EPS growth of -180.9%, a dividend yield of 0.0%. What stands out right now is revenue -1.6%, EPS -180.9%, free cash flow +104.7% with operating margin -31.7% and ROIC -41.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MYGN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-1.6% vs +7.6% peer median
Operating Margin
Below sector median
-31.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -1.6% and EPS is at -180.9%, with operating margin around -31.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -8.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | -18.3% | -19.1% | -12.5% |
2026 Feb 23, 2026 | +300.0% | +1.1% | +14.4% | +6.4% |
2025 Nov 3, 2025 | -1200.0% | -21.0% | -20.8% | -14.2% |
Benchmark Edge
MYGN vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MYGN
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MYGN Max Drawdown
-56.60%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MYGN and SPY.
Company Overview
Myriad Genetics, Inc.
NASDAQ Global Select
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
- Leadership
- Samraat S. Raha
- IPO Date
- Oct 6, 1995
- Employees
- 2.7k
- Street Address
- 320 Wakara Way
- Mailing
- Salt Lake City, UT, 84108
- Region
- Salt Lake City, UT, US
- Reporting Currency
- USD
- Investor Line
- 801 584 3600
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.5
- Price/Book
- 1.2
Growth
- Revenue
- -1.6%
- EPS
- -180.9%
- Free Cash Flow
- +104.7%
Profitability
- Gross Margin
- 69.9%
- Operating Margin
- -31.7%
- Net Margin
- -44.4%
- ROE
- -79.8%
- ROIC
- -41.8%
Balance Sheet
- Debt/Equity
- 0.57
- Current Ratio
- 2.49
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.